Clinical trials: DCIS
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
This randomized pilot clinical trial studied whether the Oncotype DX gene expression "Recurrence Score" (RS) would be useful for helping make a decision about which type of pre-operative treatment, hormone therapy or chemotherapy…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT01293032
- Testing
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer
Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast
We hypothesize that the combination of mammography and CE-MRI will improve the surgeon and radiologist's ability to define extent of disease prior to surgical resection, improve the odds of obtaining clear surgical margins, and…
- Trial name
- NCT00556907
- Testing
- Intraoperative radiotherapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Southern California
Breast Cancer
Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin may keep cancer from coming back in women who are at high risk for a new breast cancer after…
- Trial name
- NCT00334542
- Testing
- simvastatin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Female Breast Carcinoma, Female Ductal Carcinoma In Situ
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
This is an open-label, non-randomized pharmacokinetic study of fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified with breast cancer or DCIS.
- Trial name
- 007 (NCT02540330)
- Testing
- Fulvestrant
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Atossa Therapeutics, Inc.
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy).
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ
- Trial name
- NCT02314156
- Testing
- Telapristone Acetate, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Northwestern University
Ductal Carcinoma in Situ
Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast
The purpose of this study is to establish the utility of lapatinib in the treatment of DCIS, particularly ER-negative DCIS.
- Trial name
- NCT00857714
- Testing
- lapatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Indiana University
Breast Neoplasms
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
The primary goal of this 5-year study is to determine whether exemestane alone or in combination with celecoxib decreases breast tissue density in healthy postmenopausal women at high risk for breast cancer.
- Trial name
- NCT00073073
- Testing
- Exemestane, Calcium carbonate, Vitamin D
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Georgetown University
Breast Cancer, Ductal Carcinoma in Situ - Category
Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
This prospective, one-arm study which will enroll participants with biopsy-proven DCIS scheduled for diagnostic breast MRI for preoperative staging/extent of disease evaluation as part of standard of care.
- Trial name
- NCT03703492
- Testing
- (18F)FES, Gadobenate dimeglumine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer, Ductal Carcinoma in Situ
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
This study will evaluate the local control rate, cosmetic results, and complication rates of breast brachytherapy delivered using the MammoSite-ML® when used as the sole method of radiation therapy or as a boost technique for…
- Trial name
- Mammosite ML (NCT01448447)
- Testing
- Mammosite ML
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mercy Research
DCIS
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
Breast cancer is one of the most common cancers seriously afflicting women in the United States. Of the one million incident cases that are reported annually there are approximately 193,000 new cases of breast cancer (Greenlee…
- Trial name
- NCT00256217
- Testing
- Anastrozole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Rita Sanghvi, Mehta
Ductal Breast Carcinoma In Situ, HER2/Neu Positive
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ.
- Trial name
- NCT00555152
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Breast Ductal Carcinoma In Situ
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
This phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or sargramostim works in treating patients with breast cancer.
- Trial name
- NCT02636582
- Testing
- Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT02993159
- Testing
- Afimoxifene, Laboratory Biomarker Analysis, Tamoxifen Citrate
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University